MK-6194

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for MK-6194, covering 2024-10-21 to 2026-08-10. Get the full timeline:

Most recent: Clinical Trial Results: Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) [Phase 2]